| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | Deficiência visual
> Deficiência visual | Parceria regulatória
> A trabalhar com organismos reguladores | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | Deficiência visual
> Degenerescência macular | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Neurológico
> Esclerose múltipla | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | Respiratório
> DPOC | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | Respiratório
> Asma e alergia | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | Respiratório
> Asma e alergia | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | Pele
> Condições de pele: a maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | Cancro
> Cancro: sangue | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | Gastrointestinal
> Gastrointestinal: maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | Cardiovascular
> Doenças cardiovasculares & cardíacas | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Saúde geral
> Saúde geral | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | Cancro
> Cancro: pele | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 5000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Defesa do doente
> Ativista de saúde | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defesa do doente
> Ativista de saúde | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | Respiratório
> Doenças pulmonares | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | Raro
> Doenças raras: outras | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 1000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cancro
> Cancro: mama | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cancro
> Cancro: a maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 1000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Pele
> Alopecia | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 5000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratório
> Fibrose pulmonar | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cancro
> Cancro: sangue | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 5000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | Cancro
> Cancro: bexiga | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | Deficiência visual
> Deficiência visual | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: a maioria dos tipos | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 1000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Doença de Pompe | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | Respiratório
> Fibrose pulmonar | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: colorretal | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 10 000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Saúde geral
> Obesidade | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | Saúde geral
> Obesidade | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | 100 000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | Educação do doente
> Educação do doente | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | Respiratório
> Doenças pulmonares | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | Reumático
> Lúpus | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Deficiência visual
> Deficiência visual | Parceria regulatória
> Participar em avaliações de Avaliação de Tecnologias de Saúde (ATS) e de reembolso | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | Deficiência
> Deficiência: outra | Parceria regulatória
> Contribuir para submissões de Autorização de Introdução no Mercado | 5000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Pessoas mais velhas
> Pessoas mais velhas | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 100 000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | Cancro
> Cancro: mama | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | 100 000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | Raro
> Doenças raras: sangue | Parceria regulatória
> Participar/facilitar reuniões com decisores políticos/reguladores | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | Sangue
> Doença das células falciformes | Parceria regulatória
> Com outros defensores de saúde | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Deficiência visual
> Degenerescência macular | Impacto nas políticas e legislação
> Influenciar a política e legislação de saúde | 100 000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Pessoas mais velhas
> Pessoas mais velhas | Impacto nas políticas e legislação
> Influenciar a política e legislação de saúde | 10 000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | Pele
> Condições de pele: a maioria dos tipos | Impacto nas políticas e legislação
> Participar em audiências públicas e consultas | 100 000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | Reumático
> Esclerodermia | Impacto nas políticas e legislação
> Participar em audiências públicas e consultas | 5000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | Raro
> Doenças raras: genética | Impacto nas políticas e legislação
> Mobilizar parlamentares e líderes políticos | 1000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | Pessoas mais velhas
> Pessoas mais velhas | Impacto nas políticas e legislação
> Mobilizar parlamentares e líderes políticos | 100 000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Pessoas mais velhas
> Pessoas mais velhas | Impacto nas políticas e legislação
> Mobilizar parlamentares e líderes políticos | 10 000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cancro
> Cancro: sangue | Impacto nas políticas e legislação
> Abordar barreiras/anomalias nos cuidados médicos | 1000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | Deficiência visual
> Deficiência visual | Impacto nas políticas e legislação
> Abordar barreiras/anomalias nos cuidados médicos | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cancro
> Cancro: sangue | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 5000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Defesa do doente
> Ativista de saúde | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurológico
> Epilepsia | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 1000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | Cancro
> Cancro: sangue | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 5000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Doença de Pompe | Defesa de preços e acessibilidade financeira
> Defender preços justos para medicamentos | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | Cancro
> Cancro: sangue | Defesa de preços e acessibilidade financeira
> Participar em negociações do conselho de revisão de preços | 5000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | Imune
> Imunodeficiências primárias | Defesa de preços e acessibilidade financeira
> Participar em negociações do conselho de revisão de preços | 5000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Pessoas mais velhas
> Pessoas mais velhas | Defesa de preços e acessibilidade financeira
> Participar em negociações do conselho de revisão de preços | 10 000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | Deficiência visual
> Deficiência visual | Defesa de preços e acessibilidade financeira
> Participar em negociações do conselho de revisão de preços | 100 000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | Cancro
> Cancro: sangue | Defesa de preços e acessibilidade financeira
> Solicitar preços de venda reduzidos aos fabricantes | 10 000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Imune
> Imunodeficiências primárias | Defesa de preços e acessibilidade financeira
> Monitorização e acompanhamento de preços de medicamentos/escassez de medicamentos | 5000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | Neurológico
> Epilepsia | Defesa de preços e acessibilidade financeira
> Monitorização e acompanhamento de preços de medicamentos/escassez de medicamentos | 5000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | Cancro
> Cancro: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Monitorização e acompanhamento de preços de medicamentos/escassez de medicamentos | 1000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | Saúde mental
> Saúde mental: perturbações do humor | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 10 000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | Imune
> Imunodeficiências primárias | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 5000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | Neurológico
> Epilepsia | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | Respiratório
> Fibrose pulmonar | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 100 000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | Deficiência visual
> Deficiência visual | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | Raro
> Doença de Pompe | Defesa de preços e acessibilidade financeira
> Defender a inclusão do produto em listas de reembolso/formulários nacionais | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | Pele
> Condições de pele: a maioria dos tipos | Defesa de preços e acessibilidade financeira
> Participar em campanhas de sensibilização | 100 000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | Cancro
> Cancro: sangue | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 1000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | Reumático
> Lúpus | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 5000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | Defesa do doente
> Ativista de saúde | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | Raro
> Doenças raras: outras | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 1000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurológico
> Epilepsia | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | Cancro
> Cancro: a maioria dos tipos | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 1000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | Cancro
> Cancro: sangue | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 5000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | Deficiência visual
> Deficiência visual | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | Cancro
> Cancro: sangue | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 5000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Saúde geral
> Obesidade | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | 100 000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | Reumático
> Lúpus | Melhorar os caminhos de acesso
> Facilitar o acesso equitativo a medicamentos/cuidados de saúde | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | Pessoas mais velhas
> Pessoas mais velhas | Melhorar os caminhos de acesso
> Defender um acesso mais amplo às vacinas | 10 000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | Deficiência visual
> Deficiência visual | Melhorar os caminhos de acesso
> Abordar disparidades no acesso e gestão | 100 000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | Cancro
> Cancro: sarcoma | Melhorar os caminhos de acesso
> Melhorar o acesso a terapias raras/ultra-raras | 5000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | Defesa do doente
> Ativista de saúde | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | Pele
> Alopecia | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 5000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | Raro
> Doença de Pompe | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | Saúde geral
> Obesidade | Contribuição do doente baseada em evidências
> Utilize os insights dos pacientes para informar decisões | 100 000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defesa do doente
> Ativista de saúde | Contribuição do doente baseada em evidências
> Fornecer Evidências do Mundo Real (RWE) a agências reguladoras | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | Reumático
> Lúpus | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Saúde geral
> Saúde geral | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | 10 000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defesa do doente
> Ativista de saúde | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | 1000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | Cancro
> Cancro: a maioria dos tipos | Contribuição do doente baseada em evidências
> Aproveite histórias de pacientes e narrativas de experiências vividas | 1000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | Defesa do doente
> Ativista de saúde | Contribuição do doente baseada em evidências
> Realizar inquéritos/pesquisas para gerar dados | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | Deficiência visual
> Deficiência visual | Contribuição do doente baseada em evidências
> Realizar inquéritos/pesquisas para gerar dados | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> VIH e saúde sexual | Governação institucional
> Garantir representação nos órgãos consultivos governamentais | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | Gastrointestinal
> Gastrointestinal: maioria dos tipos | Governação institucional
> Garantir representação nos órgãos consultivos governamentais | 100 000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | Pessoas mais velhas
> Pessoas mais velhas | Governação institucional
> Garantir representação nos órgãos consultivos governamentais | 10 000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | Cancro
> Cancro: sangue | Governação institucional
> Garantir representação nos órgãos consultivos governamentais | 5000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | Cancro
> Cancro: sarcoma | Governação institucional
> Garantir representação nos órgãos consultivos governamentais | 5000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | Neurológico
> Epilepsia | Governação institucional
> Trabalhar eficazmente em redes com múltiplos intervenientes | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> VIH e saúde sexual | Defender os direitos dos doentes/melhorar a qualidade de vida
> Proteger/melhorar a experiência do doente | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | Defender os direitos dos doentes/melhorar a qualidade de vida
> Proteger/melhorar a experiência do doente | 1000 | Local | Regularly | 119045557717 |